Lv3
384 积分 2025-01-02 加入
In vivo manufacture and manipulation of CAR-T cells for better druggability
5小时前
已完结
In vivo CAR T cells move into clinical trials
5小时前
已完结
Defining immune reset: achieving sustained remission in autoimmune diseases
1个月前
已完结
Inherited human IRAK-4 deficiency: an update
1个月前
已完结
Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B
1个月前
已完结
OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
1个月前
已完结
AML-147 C-MYC Targeting by Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Exerts Profound Cell Kill In Vitro and In Vivo in Acute Myeloid Leukemia and Lymphomas
1个月前
已完结
A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together
1个月前
已完结
Structure of the human PKD1-PKD2 complex
1个月前
已完结
Autosomal dominant polycystic kidney disease
2个月前
已完结
皖公网安备34019202002308
